Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity

Chimeric antigen receptor (CAR) T cell therapy has led to impressive clinical responses in patients with hematological malignancies; however, its effectiveness in patients with solid tumors has been limited. While CAR T cells for the treatment of advanced prostate and pancreas cancer, including thos...

Descripción completa

Detalles Bibliográficos
Autores principales: Murad, John P., Tilakawardane, Dileshni, Park, Anthony K., Lopez, Lupita S., Young, Cari A., Gibson, Jackson, Yamaguchi, Yukiko, Lee, Hee Jun, Kennewick, Kelly T., Gittins, Brenna J., Chang, Wen-Chung, Tran, Chau P., Martinez, Catalina, Wu, Anna M., Reiter, Robert E., Dorff, Tanya B., Forman, Stephen J., Priceman, Saul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261088/
https://www.ncbi.nlm.nih.gov/pubmed/33647456
http://dx.doi.org/10.1016/j.ymthe.2021.02.024

Ejemplares similares

Ejemplares similares